TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00721331

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline HCl + loratadine
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline HCl + loratadine
Description: Topical

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nortriptyline HCl
Description: Topical

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mometasone furoate
Description: Topical

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Active ingredient free vehicle cream of CRx-197
Description: Topical
Study: NCT02635282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intranasal ketamine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal fentanyl

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intranasal midazolam
Study: NCT00476931

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SB-509
Description: 60 mg dose

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study: NCT05084547

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT00542347

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esomeprazole first
Description: * esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Generic omeprazole first
Description: * generic omeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7~* followed by washout for 7 days~* esomeprazole 20mg po once per day for 7 days~* 24hr pH study on day 7
Study: NCT02959879

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: curative surgery for resectable pancreatic duct adenocarcinoma
Description: curative surgery for resectable pancreatic duct adenocarcinoma

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard adjuvant chemotherapy
Description: 12 cycles of standard adjuvant chemotherapy are administrated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: 8 cycles of standard adjuvant chemotherapy are administrated

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adjuvant chemotherapy
Description: 8 cycles of standard adjuvant chemotherapy are administrated
Study: NCT03423654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spatial Training
Description: Spatial Training using a 5x5 grid

Intervention type: OTHER
Group type: OTHER
Intervention: Letter number matching
Description: Letter number matching
Study: NCT02956096

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial direct current stimulation (tDCS)
Description: The active tDCS and placebo will be applied to anode electrode on left temporal cortex placed on the scalp in the region T3. The cathode electrode on the middle deltoid muscle contralateral to the anode.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: training on the running belt
Description: The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: training on the running belt
Description: The running in the treadmill will be held on a single training session and the speed of the cardiopulmonary exercise testing and slope from 60 to 80% of the maximum achieved in cardiopulmonary testing, in order that the patient reaches 60% to 70% of the heart rate reserve.
Study: NCT01665508

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nebivolol
Description: Patient to start nebivolol and have repeat testing in 3 months
Study: NCT01748773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Participants will receive oxaliplatin 100 mg/m\^2 IV on Day 1 of Cycles 1-3.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Participants will receive radiotherapy at total dose of 45 Gy divided into 25 doses, 5 treatments per week for 5 weeks starting on Day 1 of Cycle 4.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Participants will receive capecitabine 850 mg/m\^2 orally twice daily on Days 1-14 of Cycles 1-3 and on 5 days per week during chemoradiotherapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Participants will receive trastuzumab 8 mg/kg IV on Day 1 Cycle 1, 6 mg/kg IV on Day 1 of each following 3-week cycle for 12 months (a total of 17 doses).
Study: NCT00235027

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adverse Drug Event Monitoring
Description: The intervention in this study is the presentation of medication safety alerts in the electronic medical record to improve patient outcomes and safety.
Study: NCT04583423

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3655
Description: MK-3655 50, 100 or 300 dose for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3655
Description: MK-3655 50, 100 or 300 dose for injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-3655
Description: MK-3655 50, 100 or 300 dose for injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo to MK-3655
Study: NCT02013882

Intervention type: PROCEDURE
Intervention: 1-1-12 wash-in
Description: wash-in phase during start of low flow anesthesia
Study: NCT00955838

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation technique
Description: 12 therapy session

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Rehabilitation technique
Description: 12 therapy session
Study: NCT02811003

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Rotation Medical Bioinductive Implant
Description: Placement of bioinductive implant over repair of insertional Achilles tendinopathy
Study: NCT03071562

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Yoga-mindfulness
Description: Sample class:~Warm-up~(15 minutes) Standing poses~(15 minutes) Balance poses~(15 minutes) Abdominals \& back bends (10 minutes) Cool-down~(5 minutes) Seated meditation Alternate nostril breathing Bellows breath Shoulder/neck stretches Cat-cow Forward fold Sun salutations Warrior 1 Warrior 2 Triangle Extended side angle Reverse warrior High lunge with twist Tree pose Standing holding knee Modified warrior 3 (chair support) Half moon~Bird-dog Side plank Bridge Cobra Sphinx Corpse pose Side-lying Seated om~Every month, a smudging ceremony will take place with an Aboriginal Elder for 5-10 minutes at the start of the class.
Study: NCT01884701

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENABLER-P Catheter System
Study: NCT00473954

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: EGEN-001 (phIL-12-005/PPC)
Description: In stage 1, patients will receive standard doses of IV carboplatin and docetaxel for 2 treatment cycles with a 3 week interval. Patients will also receive 4 IP infusions of EGEN-001 at 12mg/m2 EGEN-001, 18mg/m2, or 24mg/m2, 10-11 days apart.~Stage 2 of the study will involve cycle escalation at the highest EGEN-001 dose identified from Stage 1. All patients will receive up to 8 doses of EGEN-001, 10-11 days apart plus up to 4 IV carboplatin and docetaxel cycles with 3 week intervals. After receiving the assigned number of treatments of EGEN-001, carboplatin, and docetaxel, patients may continue to receive up to 4 additional infusions of EGEN-001 and 2 IV carboplatin and docetaxel cycles with 3 week intervals.
Study: NCT00525746

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview lasting about 50 minutes.

Intervention type: BEHAVIORAL
Intervention: Interview
Description: Interview lasting about 50 minutes.
Study: NCT04281472

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: efgartigimod PH20 SC in stage B
Description: Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: efgartigimod PH20 SC in stage B
Description: Stage A: efgartigimod PH20 SC, Stage B: efgartigimod PH20 SC

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo in stage B
Description: Stage A: N/A, stage B: placebo
Study: NCT02768701

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Subjects will be treated every 3 weeks with 200 mg of pembrolizumab via a 30 minute infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: A single 300 mg/m2 dose of cyclophosphamide IV over 30-60 minutes will be administered on Day 1 of this study.
Study: NCT04581304

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Geistlich Bio-Oss® Collagen
Description: Geistlich Bio-Oss® Collagen is intended to be used for filling bone defects and for bone augmentation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Oss® Granules
Description: Geistlich Bio-Oss® Granules is intended to be used for filling bone defects and for bone augmentation.
Study: NCT03168126

Intervention type: DEVICE
Intervention: Pro-AQT
Description: Use of the device for advanced hemodynamic monitoring
Study: NCT03566017

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pegunigalsidase alfa
Description: Recombinant human alpha galactosidase A
Study: NCT03424915

Intervention type: BEHAVIORAL
Intervention: Harvard Health Professionals survey
Description: Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.

Intervention type: BEHAVIORAL
Intervention: Harvard Health Professionals survey
Description: Participants will be asked a series of questions (using a validated questionnaire) to assess self-reported exercise exposure over the past 12 months.

Intervention type: OTHER
Intervention: Blood draw
Description: Participant will provide a blood sample

Intervention type: OTHER
Intervention: CPET Procedures
Description: CPET with 12-lead ECG

Intervention type: OTHER
Intervention: stool sample
Description: Research stool sample (within ±1 week of surgery), if possible

Intervention type: PROCEDURE
Intervention: Research Tissue sampling
Description: Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
Study: NCT00799864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenofovir disoproxil fumarate
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for 240 weeks (Cohort 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamivudine
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Emtricitabine
Description: Type=exact, form=appropriate pediatric formulation, unit=mg, route=oral. The patients may receive this selected NRTI together with another NRTI once daily for up to 48 weeks (Cohort 2) and 240 weeks (Cohort 1).
Study: NCT03728231

Intervention type: OTHER
Intervention: Complete blood count
Description: taking blood sample from venous blood

Intervention type: OTHER
Intervention: Complete blood count
Description: taking blood sample from venous blood

Intervention type: OTHER
Intervention: Complete blood count
Description: taking blood sample from venous blood
Study: NCT03133780

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ketamine
Description: Patient will receive IV ketamine 0.5 mg/kg diluted in normal saline to a volume of 50 ml over 10 min

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Patient will receive IV midazolam 0.03 mg/kg diluted in normal saline to a volume of 50 ml over 10 min
Study: NCT03024671

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Patch test application
Description: test patch with cosmetic product will be applied to the back
Study: NCT02048813

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Given IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fludarabine Phosphate
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibrutinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Pharmacogenomic Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Given IV

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Given IV
Study: NCT01660685

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tracking
Description: Participants will record their daily weight, physical activity steps and meal replacements online

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Journaling
Description: Participants will journal to two online writing prompts: one on positive focus and one on goal setting

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Website
Description: Participants will have access to resource website with stories and tips from people who successfully lost weight, blogs from investigators, quotes from other participants.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Enhanced Usual Care
Description: Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Enhanced Usual Care
Description: Participants will receive standard care of monthly height, weight and blood pressure measurements. Participants will also receive a pedometer and a diet plan book on pre-portioned items.
Study: NCT01433588

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Calmer
Description: This platform, called the Calmer, interacts with the infant to help reduce stress to help promote better outcomes. Infants can be placed on it for care to mimic Kangaroo Care, maternal skin to skin.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of Care
Description: Infant would receive the standard of care for bloodwork, provided a soother and facilitated tucking.
Study: NCT04010253

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: SIMEOX
Description: Instrumental airway clearance by the medical device SIMEOX

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Autogenic drainage
Description: Manual aiway clearance by autogenic drainage
Study: NCT05025917

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Shatavari
Description: Shatavari root powder
Study: NCT04112264

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Monopolar radiofrequency ablation
Description: a radiofrequency cannula is advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia along the area of knee joint supplied by that respected genicular nerve by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
Study: NCT05025917

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Magnesium stearate
Description: Magnesium stearate powder
Study: NCT01986322

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: DTP/HB/Hib vaccine
Description: Dosage equal to 0.5 mL administered intramuscularly

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: DTP/HB and Hib vaccine
Description: Dosage equal to 0.5 mL administered intramuscularly
Study: NCT00629642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Oral, 10mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Solifenacin Succinate
Description: Oral, 5mg
Study: NCT04112264

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bipolar radiofrequency ablation
Description: Two radiofrequency cannula are advanced under USG guidance towards the nerve. The final position will be confirmed by using nerve stimulator with elicitation of paraesthesia by stimulation at 50 Hz current of \<0.5 mV. The motor stimulation will be negative at all instances. For each genicular nerve, two conventional RF lesions are done for 120s at 80° of temperature using the Neurotherm 1100 RF generator.
Study: NCT03424915

Intervention type: PROCEDURE
Intervention: Research Tissue sampling
Description: Sample of the tumor and normal breast tissue may be taken from the tissue removed during breast cancer surgery if there is enough tissue left over for research testing.
Study: NCT02036086

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobimetinib
Description: Drug
Study: NCT01328652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole
Description: dexlansoprazole 60 mg once daily for 3 months
Study: NCT01698645

Intervention type: DRUG
Intervention: PecFent® (fentanyl) nasal spray
Study: NCT00391365

Intervention type: PROCEDURE
Intervention: Gait analysis
Description: Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.

Intervention type: PROCEDURE
Intervention: Gait analysis
Description: Subjects will come into motion analysis laboratory at the VA Puget Sound Health Care System. A standard set of body measurements will be taken using calipers, a measuring tape, and a scale (for example height, weight, leg length, foot length, etc). The investigators will then attach small reflective markers to the body using double-sided tape and ask the participants to walk several times as the motion of each marker is recorded by infrared cameras.
Study: NCT01559363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: Pharmaceutical form: Tablets Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: Pharmaceutical form: Tablets Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: Pharmaceutical form: Tablets Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: Pharmaceutical form: Tablets Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: Pharmaceutical form: Tablets Route of administration: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tesevatinib
Description: Pharmaceutical form: Tablets Route of administration: Oral
Study: NCT03669861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abatacept
Description: Subjects will receive weekly subcutaneous doses of abatacept (125mg) for 24 doses (24 weeks)
Study: NCT00833300

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: * 2.5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg IV q6h for 24 hours and 2.5 mg-5 mg IV prn, up to 40 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Olanzapine
Description: * 2.5 mg-10 mg po/ng/og bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Increase dose 5 mg-10 mg bid and 2.5 mg po/ng/og prn, up to 20 mg in 24 hours.~* Reassess in 24 hours.~* Delirium absent - Continue dose for 24 hours then discontinue.~* Delirium present - Discontinue current drug therapy and select one of:~  1. Quetiapine up to 100 mg/day~ 2. Risperidone up to 6 mg/day~ 3. Loxapine up to 50 mg/day~ 4. Methotrimeprazine up to 75 mg/day~* Reassess in 24 hours.~* Delirium absent - Continue for 24 hours then discontinue.~* Delirium present - Treatment at discretion of attending physician.
Study: NCT02287480

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: VSV-ZEBOV
Description: See arm/group descriptions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-ZEBOV
Description: See arm/group descriptions.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: VSV-ZEBOV
Description: See arm/group descriptions.
Study: NCT01689077

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Therapeutic hypothermia
Description: Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Therapeutic hypothermia
Description: Mild therapeutic hypothermia with a target temperature of 33 degrees Centigrade for 24 or 48 hours
Study: NCT01897207

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Dendritic cell application
Description: S.C. injection of peptide pulsed autologous dendritic cells